Healthcare Triangle Inc

Análisis de la acción Healthcare Triangle Inc (HCTI)

$3.690

+0.103 (+2.79%)Al cierre

Loading chart…
Máximo
3.830
Apertura
3.710
Precio medio ponderado por volumen
3.72
Volumen
10.60K
Capitalización
2.90M
Mínimo
3.650
Importe
39.48K
EV/EBITDA, TTM
-0.90

Healthcare Triangle, Inc. is a healthcare information technology company. The Company is focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry. Its Software Services segment provides strategic advisory, implementation, and development services. Its Managed Services and Support segment includes post-implementation support and cloud hosting. Its Customer Engagement Services provide customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. The Company's proprietary platforms include CloudEz, DataEz, Readabl.AI, Ziloy, and Ezovion. Through its platform, solutions, and services, the Company supports healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and life sciences, biotech companies, and medical device manufacturers.

Análisis de IA of Healthcare Triangle Inc (HCTI)

Vender

HCTI is not a good buy right now due to its extremely low RSI of 15.487, indicating it is oversold, and a staggering year-to-date change of -99.50%, which reflects severe declines in value. The company has also reported consistent net losses, with a net income of -6198000 in Q1 2026 and -4415000 in Q2 2026, which raises concerns about its financial health. The main risk is the potential for further declines in stock price, given its current position at 0.0% of the 52-week range, indicating it is trading at its lowest point.

Métricas de valoración

El PER previsto actual de Healthcare Triangle Inc (HCTI) es 0.00, frente a su media de 5 años de -1.43.

PER previsto

Valor razonable
Media 5A P/E
-1.43
P/E actual
0.00
Sobrevalorada
1.31
Infravalorada
-4.16

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-0.67
EV/EBITDA actual
-0.90
Sobrevalorada
13.32
Infravalorada
-14.66

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.32
P/S actual
0.08
Sobrevalorada
0.69
Infravalorada
-0.05

Cronología de eventos

2026-11-02 (ET)

09:30:00

Healthcare Triangle Expands Potential Business in Indonesia to $45M

2026-10-20 (ET)

09:30:00

Healthcare Triangle's Teyame Signs Six Client Engagements, Estimated Annual Revenue of $1.34M

2026-09-30 (ET)

14:30:00

Healthcare Triangle Signs MOU with AI World

2026-09-23 (ET)

09:30:00

Healthcare Triangle Signs LOI to Acquire Roboticom

2026-09-03 (ET)

09:30:00

Healthcare Triangle Signs Separation Agreement with Teyame AI Holdings

Noticias

Preguntas frecuentes sobre HCTI, respondidas por Alphio AI

Healthcare Triangle, Inc. is a healthcare information technology company. The Company is focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry. Its Software Services segment provides strategic advisory, implementation, and development services. Its Managed Services and Support segment includes post-implementation support and cloud hosting. Its Customer Engagement Services provide customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. The Company's proprietary platforms include CloudEz, DataEz, Readabl.AI, Ziloy, and Ezovion. Through its platform, solutions, and services, the Company supports healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and life sciences, biotech companies, and medical device manufacturers. It operates in the Technology sector (SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN industry).

HCTI is not a good buy right now due to its extremely low RSI of 15.487, indicating it is oversold, and a staggering year-to-date change of -99.50%, which reflects severe declines in value. The company has also reported consistent net losses, with a net income of -6198000 in Q1 2026 and -4415000 in Q2 2026, which raises concerns about its financial health. The main risk is the potential for further declines in stock price, given its current position at 0.0% of the 52-week range, indicating it is trading at its lowest point.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar